TTrialPathMatch Me to Trials
← Back to trials
RecruitingPulmonary Disease, Chronic Obstructive

A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Eligible age

40–80 yrs

Accepts

All genders

Locations

8 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.

Sponsor: GlaxoSmithKline

You may qualify if…

  • ✓ Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent
  • ✓ Basal Metabolic Rate (BMI) \>= 16 kilogram per meter square (kg/m\^2)
  • ✓ Moderate to severe COPD with frequent exacerbations, defined as
  • ✓ a clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year prior to the screening visit;
  • ✓ a post-salbutamol FEV1/Forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post-salbutamol FEV1 greater than (\>) 30 percent (%) and \>= 80% predicted normal values calculated withGlobal Lung Function Initiative (GLI) - Global Race Neutral equations in line with the American Thoracic Society (ATS) recommendations at screening;
  • ✓ a well-documented history (e.g., medical record verification, including capturing of all prior biologic use) of at least 2 moderate or 1 severe exacerbations in the 12 months prior to screening despite the use of Inhaled Corticosteroids (ICS) containing maintenance COPD treatment; at least one qualifying exacerbation must have occurred while participant was on ICS plus long-acting muscarinic antagonist (LAMA) plus long-acting beta agonist (LABA); Moderate exacerbations must have been treated with systemic corticosteroids and/or antibiotics (subcutaneous \[SCS\]; Intramuscular \[IM\], Intravenous \[IV\], or oral); Severe exacerbations are those requiring hospitalization or observation \>24 hours in the emergency department /urgent care facility
  • ✓ Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening. Former smokers are defined as those who have stopped all cigarette smoking for at least 6 months prior to the Screening Visit
  • ✓ An eosinophilic phenotype with elevated Blood eosinophil count (BEC) at screening

You may not qualify if…

  • ✕ Participants with a current or prior physician diagnosis of asthma are excluded
  • ✕ Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Participants with α1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • ✕ COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening are excluded
  • ✕ Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure are excluded
  • ✕ Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to the Screening Visit are excluded. Participants who are in the maintenance phase of a pulmonary rehabilitation program may participate
  • ✕ Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day are excluded. Non-continuous (i.e., 12 hours or less per day) oxygen is permitted up to 2 Liters per minute (L/min) at the time of the screening visit and for the duration of the study. Participants on long term oxygen therapy (LTOT) should be ambulatory and able to attend clinic visits
  • ✕ Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension is excluded
  • ✕ Chronic hypercapnia requiring Non-invasive Positive Pressure Ventilation (NIPPV) use (including Bilevel Positive Airway Pressure \[BiPAP\] or Continuous positive airway pressure \[CPAP\]) are excluded

Where it's recruiting

California

Newport Beach

Florida

Miami

Kansas

Derby

Maryland

Columbia

Oklahoma

Oklahoma City

Pennsylvania

Philadelphia

Texas

Tomball

Source: ClinicalTrials.gov · NCT07915791 · last updated 2026-11-17